Immune-mediated adverse reactions
|
Pneumonitis
|
Grade 2
|
Withholdb
|
Grade 3 or 4
|
Permanently discontinue
|
Colitis
|
Grade 2 or 3
|
Withholdb
|
Grade 4
|
Permanently discontinue
|
Hepatitis with no tumor involvement of the liverc
|
AST or ALT increases to more than 3 and up to 8 times ULN or Total bilirubin increases to more than 1.5 and up to 3 times ULN
|
Withholdb
|
AST or ALT increases to more than 8 times ULN or Total bilirubin increases to more than 3 times ULN
|
Permanently discontinue
|
Hepatitis with tumor involvement of the liverd
|
Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN orBaseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN
|
Withholdb
|
ALT or AST increases to more than 10 times ULN or Total bilirubin increases to more than 3 times ULN
|
Permanently discontinue
|
Endocrinopathies
|
Grade 3 or 4
|
Withhold until clinically stable or permanently discontinue depending on severity
|
Nephritis with renal dysfunction
|
Grade 2 or 3 increased blood creatinine
|
Withholdb
|
Grade 4 increased blood creatinine
|
Permanently discontinue
|
Exfoliative dermatologic conditions
|
Suspected SJS, TEN, or DRESS
|
Withholdb
|
Confirmed SJS, TEN, or DRESS
|
Permanently discontinue
|
Myocarditis
|
Grade 2, 3, or 4
|
Permanently discontinue
|
Neurological toxicities
|
Grade 2
|
Withholdb
|
Grade 3 or 4
|
Permanently discontinue
|
Hematologic toxicity in patients with cHL or PMBCL
|
Grade 4
|
Withhold until resolution to Grade 0 or 1
|
Other adverse reactions
|
Infusion-related reactions
|
Grade 1 or 2
|
Interrupt or slow the rate of infusion
|
Grade 3 or 4
|
Permanently discontinue
|